secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001576885-23-000056
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront
--------------------------------------------------------------------------------

- Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.
- Milestone payments tied to development/commercialization and net sales levels; single-digit royalties on worldwide net sales.
- Halozyme named exclusive supplier of API for PH20 product for clinical and commercial supplies.
- Agreement covers development of a subcutaneous formulation of ACU193.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/0001576885-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/abos-20231105.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer